SSA
ARQT icon

Schonfeld Strategic Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-189,555
Closed -$3.57M – 2040
2025
Q3 		$3.57M Sell
189,555
-330,729
-64% -$5.22M 0.02% 748
2025
Q2 		$7.29M Buy
520,284
+501,818
+2,718% +$7.03M 0.06% 439
2025
Q1 		$289K Sell
18,466
-4,534
-20% -$63.9K ﹤0.01% 1808
2024
Q4 		$320K Sell
23,000
-7,349
-24% -$80.5K ﹤0.01% 1589
2024
Q3 		$282K Buy
30,349
+14,175
+88% +$140K ﹤0.01% 1679
2024
Q2 		$150K Buy
+16,174
New +$146K ﹤0.01% 1848
2023
Q1 		– Sell
-28,100
Closed -$416K – 2085
2022
Q4 		$416K Buy
+28,100
New +$491K ﹤0.01% 1627
2022
Q2 		– Sell
-17,996
Closed -$347K – 2515
2022
Q1 		$347K Buy
+17,996
New +$304K ﹤0.01% 1596

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return